Lineage Cell Therapeutics, Inc.
LCTX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | 0.44 | 0.18 | -0.11 |
| FCF Yield | -23.52% | -15.54% | 0.33% | -5.93% |
| EV / EBITDA | -2.75 | -6.48 | -8.77 | -7.24 |
| Quality | ||||
| ROIC | -21.43% | -27.18% | -21.77% | -33.98% |
| Gross Margin | 96.48% | 92.50% | 95.05% | 63.40% |
| Cash Conversion Ratio | 1.24 | 1.33 | -0.04 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | -13.55% | 31.92% | 166.94% | 38.14% |
| Free Cash Flow Growth | 19.09% | -4,626.32% | 102.70% | -20.68% |
| Safety | ||||
| Net Debt / EBITDA | 2.07 | 1.35 | 0.34 | 1.10 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,258.45 | -1,084.73 | -1,192.41 | 3,856.12 |